Colchicine in Moderate Symptomatic COVID-19 Patients
Status:
Completed
Trial end date:
2020-12-10
Target enrollment:
Participant gender:
Summary
This is a prospective, double blind, randomized, placebo controlled clinical trial. The
participants will be randomized into two groups (group A and group B). Patients of group-A
are the treatment group. They will be treated with optimal treatment based on the algorithm
proposed in National Guidelines on Clinical Management of Coronavirus Disease 2019 (Covid-19)
Version 7.0, 28 May 2020, along with Colchicine for 14 days. The patients in group-B will be
controlled group. They will be treated with optimal treatment based on the algorithm proposed
in National Guideline along with a placebo.